Elanco Animal Health Inc

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elanco Animal Health reports mixed 2022 results, eyes innovation growth

Elanco Animal Health's 2022 performance showed revenue decline but EPS growth, with a focus on innovation and portfolio strength for future growth.
The company aims to address challenges like competitive pressures and interest expenses while leveraging opportunities in product launches and margin improvement.
Financial projections include a net leverage ratio target for 2023, with plans for debt reduction and enhanced cash flow generation in the coming years.
Elanco's strategic focus on OTC parasiticides, innovation, and operational efficiency positions it well for sustained growth and market differentiation.

Elanco Animal Health reports Q1 growth and strategic outlook

Elanco Animal Health's Q1 2023 performance showcased revenue growth, strategic advancements, and improved cash flow generation, supported by successful ERP system integration benefits.
Despite challenges related to free cash flow, inventory discrepancies, and regulatory discussions, the company remains focused on optimizing working capital and enhancing financial metrics.
Opportunities lie in debt repayment, maintaining pricing benefits, upcoming product launches, and returning to growth in the second half of 2023, underpinned by global macro trends.
Elanco's strengths in market positioning, innovation progress, and strategic outlook for 2024 position the company for sustained growth and operational excellence in the animal health sector.

Elanco Animal Health surpasses Q2 targets, eyes global market growth

Elanco Animal Health exceeded Q2 targets, focusing on innovation and market expansion. While facing challenges in certain segments, the company is optimistic about future growth opportunities through differentiated products and global market strengths.

Elanco Animal Health excels in Q3, eyes sustained growth in 2024

Elanco Animal Health delivered a strong Q3 performance, emphasizing innovation and growth in international segments. While facing challenges in U.S. Pet Health and Farm Animal generics, the company is focused on driving sustainable growth through margin expansion and new product launches. Opportunities lie in upcoming blockbuster product launches and pricing strategies for 2024.

Elanco Animal Health reports growth in Q4 2023 earnings

Elanco Animal Health's Q4 2023 performance showed revenue growth driven by innovation and Farm Animal business strength.
Strategic restructuring aims to enhance efficiency and focus on pet health, while challenges include competitive pressures and margin headwinds.
Opportunities lie in continued growth, innovation, debt reduction, and commitment to new product sales targets.
Overall, Elanco remains confident in its position and ability to navigate market challenges.

Elanco Animal Health surpasses Q1 expectations, eyes revenue growth

Elanco Animal Health's Q1 2024 performance exceeded expectations, driven by strong Pet Health and Farm Animal segment growth, alongside improved cash flow and late-stage pipeline progress.
Despite challenges like product manufacturing issues and market queries, Elanco remains focused on innovation, market positioning, and executing its value agenda.
The company is poised for revenue growth, with positive outlooks for late-stage products and opportunities to capitalize on market demand and competitive strategies.
Elanco's strategic approach to product launches, market readiness, and portfolio expansion positions it well for future growth and market leadership.

Elanco Animal Health reports strong Q3 performance and growth outlook

Elanco Animal Health's Q3 performance reflects growth in key segments and products, with a focus on debt reduction and strategic investments.
The company faces challenges in competitive markets and supply chain transitions but is poised for growth through new product launches and market adoption.
Opportunities lie in expanding product reach, driving innovation sales, and navigating pricing trends to achieve mid-single-digit growth in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MEDNAX

ModivCare

Varied companies across the vast healthcare space might have been affected differently by the COVID crisis during the first quarter.

Healthcare Stock Q1 Earnings Due on May 7: ELAN, MD, MODV

ACI Worldwide

Bausch Health Companies Inc

Lionheart Holdings

Danone SA

Delek US Hlds

FirstEnergy

Forward Air

Intel

Kohl's

Prudential

Exxon Mobil

Xerox

Poorly managed companies may not be on everyone's radar, but they're top picks for activist investors looking to boost shareholder value.

13 Stocks Activist Investors Are Buying

GREENFIELD, Ind.--(BUSINESS WIRE)--Veterinarians in the U.S. now have a new, innovative option for flea and tick control as Elanco Animal Health Incorporated (NYSE: ELAN) introduces Credelio Cat, the first oral flea and tick product for cats. Credelio Cat starts killing fleas on cats within 6 hours. The small, chewable product maintains fast-acting, sustained flea efficacy throughout the month in cats 8 weeks and older. Credelio Cat also protects against black-legged ticks throughout the month

Elanco Animal Health Introduces First Oral Flea and Tick Product for Cats, Credelio® CAT (lotilaner)

Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Elanco Animal Health Incorporated (ELAN)

Elanco's share price has come under pressure amid new concerns over a key product.

A Product Recall Crashed Elanco's Stock. Is This a Buying Opportunity?

GREENFIELD, Ind.--(BUSINESS WIRE)--Today, Elanco and Ducks Unlimited announced a partnership emphasizing the strong bond between environmental sustainability and agriculture – specifically beef cattle production – across North America. Beginning in 2021 and through 2023, Elanco will invest $50,000 annually with Ducks Unlimited to help purchase grass seed to support reseeding efforts on working lands in western Kansas. This effort aligns with Elanco's Healthy Purpose™, the company's sustainabili

Elanco Animal Health and Ducks Unlimited Announce Partnership to Advance Beef Industry Environmental Stewardship Efforts

Chewy

Freshpet

PetMed Express

Northern Star Acquisition Corp

Trupanion

Petco Health and Wellness

Not all pet companies are created equal. These pet stocks are positioned for upside as the industry witnesses steady growth.

7 Pet Stocks That Make Good Long-Term Holdings

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2021 financial results on Friday, May 7, 2021. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's we

Elanco Confirms Date and Conference Call for First Quarter 2021 Financial Results Announcement

IDEXX Laboratories

Here's how you can profit off the booming $54 billion veterinary care industry.

3 Top Pet Healthcare Stocks to Buy Now

Elanco Animal Health aims to tackle the noxious problem of ammonia emissions in livestock farming.

This New Drug Can Make Farming More Environmentally Sustainable

Mosaic

TAMPA, FL and RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / March 23, 2021 / The Mosaic Company (NYSE:MOS), one of the world's leading producers and marketers of concentrated phosphate and potash crop nutrients and AgBiome, a leader in discovering and developing innovative agricultural products from diverse microbial communities, today announced a strategic collaboration, aiming to discover, develop and launch novel biological approaches to enhancing soil fertility. The collaboration will leverage AgBiome's proprietary GENESIS™ platform that comprises the world's largest, most diverse, fully-sequenced collection of microbes coupled with innovative product discovery technology.

Mosaic and AgBiome Announce Collaboration to Develop Biological Alternatives to Enhance Soil Health

GREENFIELD, Ind.--(BUSINESS WIRE)--Based on recent misleading media coverage, a U.S. House of Representatives subcommittee chair made a request to Elanco Animal Health, Incorporated (NYSE: ELAN) to temporarily remove Seresto collars from the market. Elanco reiterates that it stands behind the safety data of Seresto generated for its registration and monitored via post-marketing surveillance. All data and scientific evaluation used during the product registration process and through Elanco's rob

Elanco Stands Behind Seresto and its Safety Profile

DENVER, March 19, 2021 /PRNewswire/ -- Morris Animal Foundation, a leader in advancing animal health, is partnering with Elanco Animal Health Incorporated (NYSE: ELAN) to better understand the incidence and prevalence of osteoarthritis (OA) in dogs using data generated by the Foundation's Golden Retriever Lifetime Study. Osteoarthritis is one of the most common causes of chronic pain in dogs, affecting approximately 14 million adult dogs in the United States alone.

Morris Animal Foundation Partners with Elanco to Improve Understanding of Canine Osteoarthritis

Elanco just completed its largest merger ever. Now it turns its attention to ambitious earnings growth goals in 2021.

After Acquiring Bayer Animal Health, Elanco Is Poised for Earnings Growth in 2021

Updated guidance for FY21 points to renewed growth in key end markets. Easier comps in FY21 will make YoY growth attractive, fueling business momentum.

Reiterating Elanco With A Buy

Elanco Animal Health Incorporated (ELAN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Elanco Animal Health Incorporated (ELAN) Might be Well Poised for a Surge

Elanco Animal Health, Inc. (ELAN) Presents at Cowen Healthcare Broker Conference Call - (Transcript)

The stock price of Elanco (NASDAQ: ELAN), a pharmaceuticals company focused on medicines for pets and livestock, has seen a solid 13% rise over the last ten trading days, while it's up 9% over the last five trading days, but we believe the stock, after the recent rally, may trend lower in the nea.

Despite A Strong Q4, Elanco Stock May See A Correction

Elanco Animal Health Inc. (ELAN) CEO Jeffrey Simmons on Q4 2020 Results - Earnings Call Transcript

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year of 2020, increased guidance for full year 2021, and provided initial guidance for the first quarter of 2021. The results reflect the inclusion of the Bayer Animal Health business that Elanco acquired on August 1, 2020. “Elanco is entering 2021 with good momentum. Fourth quarter revenue surpassed our guidance as U.S. Pet Health, U.S. Farm Ani

Elanco Animal Health Reports Fourth Quarter and Full Year 2020 Results

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced the departure of executive vice president Michael-Bryant Hicks (“Hicks”). He joined Elanco in 2018 as General Counsel and Corporate Secretary to prepare the company for IPO, build the Legal department structure for the stand-alone company, and complete the successful acquisition of Bayer Animal Health. “I am grateful to Hicks for his contributions to Elanco, providing the legal expertise we needed

Elanco General Counsel Michael-Bryant Hicks to Depart After Successful Company Stand-Up and Acquisition Completion

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announces four important innovation milestones, including two product approvals, amid a string of recent progress on its innovation commitments. Farm Animal Yesterday, the U.S. FDA approved Increxxa™ (tulathromycin injection) for the treatment of bovine respiratory disease (BRD) and swine respiratory disease (SRD). Earlier this week, Health Canada approved Experior™ 50, (lubabegron), a new concentration of E

Elanco Achieves Important Innovation Milestones, Momentum to Start 2021

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Cowen 41st Annual Health Care Conference on Tuesday, March 2, 2021. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 2:50 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 90 days. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a g

Elanco to Participate in the Cowen 41st Annual Health Care Conference

Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q4 Earnings Expected to Decline

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the BofA Securities Animal Health Virtual Summit on Thursday, February 25, 2021. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 3:30 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 90 days. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELA

News for Elanco Animal Health Inc Stock (ELAN)